---
title: "Novo Nordisk pre-market jumps as Ozempic shows better cardiovascular protection efficacy than Eli Lilly's old drug"
description: "Novo Nordisk's stock price rose 6.01% in pre-market trading, marking the largest single-day increase in a month. The reason is that its diabetes drug Ozempic outperformed Eli Lilly's Trulicity in a su"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257893504.md"
published_at: "2025-09-18T10:50:04.000Z"
---

# Novo Nordisk pre-market jumps as Ozempic shows better cardiovascular protection efficacy than Eli Lilly's old drug

> Novo Nordisk's stock price rose 6.01% in pre-market trading, marking the largest single-day increase in a month. The reason is that its diabetes drug Ozempic outperformed Eli Lilly's Trulicity in a survey of American patients, with Ozempic patients having a 23% lower risk of heart attack, stroke, or death. The study involved nearly 60,000 diabetes and heart disease patients, and Novo Nordisk announced the results at the European Association for the Study of Diabetes conference

According to the Zhitong Finance APP, Novo Nordisk (NVO.US) saw its stock price record the largest single-day increase in a month, due to its diabetes blockbuster drug Ozempic outperforming Eli Lilly's (LLY.US) older drug Trulicity in a real-world study involving certain patients in the United States.

Novo Nordisk reported at the European Association for the Study of Diabetes (EAD) conference in Vienna that Medicare patients taking Ozempic had a 23% lower risk of heart attack, stroke, or death compared to those taking Trulicity. The study tracked nearly 60,000 patients with diabetes and heart disease.

Both Ozempic and Trulicity belong to the GLP-1 class of drugs, which have revolutionized weight loss treatment. The idea that "certain drugs are more effective than others in preventing heart disease" is the cornerstone of Novo Nordisk's competition with Eli Lilly in the fiercely competitive field of obesity and related diseases. Eli Lilly continues to capture market share with its new drugs Mounjaro and Zepbound.

Novo Nordisk's stock price rose by 6.5% in Copenhagen at one point.

Another head-to-head study was also presented at Thursday's meeting, showing that Mounjaro had a similar effect to Trulicity in reducing the risk of heart attack, stroke, and death. However, these two studies are not comparable, as one was a randomized trial while the other was a real-world outcomes survey.

As of the time of writing on Thursday before the U.S. stock market opened, Novo Nordisk was up 6.01%, trading at $61.70

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 诺和诺德 ADR 恢复交易，瞬间跳水，跌幅扩大至 8.4% | 诺和诺德 ADR 恢复交易，瞬间跳水，跌幅扩大至 8.4%。风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此 | [Link](https://longbridge.com/en/news/274689185.md) |
| 诺和诺德公司确认收到 FDA 关于 Wegovy 药片电视广告的 “未命名信函” | 诺和诺德公司：确认诺和诺德收到美国食品药品监督管理局（FDA）关于 WEGOVY 药丸电视广告的 “未命名信函” 诺和诺德公司：正在与 FDA 沟通，以解决他们对 WEGOVY 药丸广告展示的担忧诺和诺德公司：确认诺和诺德收到美国食品药品监 | [Link](https://longbridge.com/en/news/275349213.md) |
| Berenberg 银行重申其对诺和诺德公司（0QIU）的买入评级 | Berenberg Bank 分析师 Kerry Holford 重申了对诺和诺德公司 (0QIU) 的买入评级，目标价为 360.00 丹麦克朗。Holford 是一位四星级分析师，成功率为 59.14%，专注于医疗保健领域。最近，德意志 | [Link](https://longbridge.com/en/news/275719942.md) |
| 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元 | 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元。 | [Link](https://longbridge.com/en/news/274805260.md) |
| 诺和诺德公司将在其爱尔兰工厂生产 Wegovy | 诺和诺德公司将在爱尔兰工厂生产 Wegovy | [Link](https://longbridge.com/en/news/275789396.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.